Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.72 |
| ▸ | CNR1 | P21554 | 2/20 | 0.72 |
| ▸ | CNR2 | P34972 | 2/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.65 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.56 |
| ▸ | CASP2 | P42575 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828949 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL531436 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL7147169 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL9256918 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL5964111 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL3990517 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL31529340 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL4000461 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL9193102 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL532448 | 0.93 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| CN-108884058-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20180327367-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | WUXI APPTEC CO., LTD (CN) | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327367-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | FAAH 3193/4885CNR1 4151/4885CNR2 4813/4885 |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | FAAH 3193/4885CNR1 4151/4885CNR2 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.